CRISPR genome engineering and viral gene delivery: A case of mutual attraction

  title={CRISPR genome engineering and viral gene delivery: A case of mutual attraction},
  author={Florian Schmidt and Dirk Grimm},
  journal={Biotechnology Journal},
The adaptation of the CRISPR/Cas9 DNA engineering machinery for mammalian cells has revolutionized our approaches to low‐ or high‐throughput genome annotation and paved the way for conceptually novel therapeutic strategies. A large part of the attraction of CRISPR stems from the small size of its two core components – Cas9 and gRNA – and hence its compatibility with virtually any available viral vector delivery system. As a result, over the past two years, four major classes of viral vectors… 

In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

How the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise in vivo genome editing is discussed and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals.

Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors.

A fast and simple protocol for small-scale packaging of CRISPR/Cas9 components into AAV vectors and a detailed protocol for large-scale production of purified AAV/CRISPR vector stocks that permit higher cleavage efficiencies in vitro and are suitable for direct in vivo applications are provided.

CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes

This work adapted clinically relevant high-capacity adenoviral vectors devoid of all viral genes for the delivery of the CRISPR/Cas9 machinery using a single viral vector to enable fast transfer of the Cas9 gene and gRNA expression units into the HCAdV genome.

Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology

A set of exciting new strategies that aim at further increasing the therapeutic index of CRISPR technologies, by reducing the size of Cas9 expression cassettes and thus enhancing their compatibility with viral gene delivery vectors are highlighted.

Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges

A topical review of recent advances to in vivo delivery of the CRISPR/Cas9 system using various packaging formats, including viral, mRNA, plasmid, and protein-based approaches, focusing on the challenges to efficacy for various delivery formats.

Tailoring non-viral delivery vehicles for transporting genome-editing tools

The recent advances in the development of non-viral delivery systems for CRISPR-Cas9 are surveyed and challenges and future directions in this field are discussed.

CRISPR/Cas9 technology as a potent molecular tool for gene therapy

The therapeutic application of the CRISPR‐Cas9 system in mutational disorders, delivery systems, as well as its advantages and limitations with a special emphasis on cancer treatment will be discussed.

Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.

This review will differ in focus from previous reviews and advance the literature on the subject by focusing on the challenges of the CRISPR/Cas9 delivery system, and on the application of nanoparticle-based delivery of CRISpr components (Cas9 and sgRNA), such as lipids and polymeric vectors.

Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.

This study defines a new strategy for the delivery of the large plasmid encoding Cas9/sgRNA for efficient genome editing, which results in efficient editing at two genome loci, namely, hemoglobin subunit beta and rhomboid 5 homolog 1.

Appropriate Delivery of the CRISPR/Cas9 System through the Nonlysosomal Route: Application for Therapeutic Gene Editing

Given their high biosafety, PAR‐Lipos are used to mediate the knockout of the oncogene CDC6 in vivo, which results in significant tumor growth inhibition, and may provide a useful reference for enhancing the delivery of gene editing systems, thus improving the potential for their future clinical applications.



CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.

A versatile set of plasmids and vectors derived from adeno-associated virus that allow robust and specific delivery of the two essential CRISPR components - Cas9 and chimeric g(uide)RNA - either alone or in combination are reported, and original evidence that AAV/CRISPR vectors can be exploited for gene engineering in vivo is provided.

Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.

All essential steps for the generation and selection of shuffled AAV libraries are described and demonstrated, and the pitfalls and critical aspects of the protocols that one needs to be aware of in order to succeed with molecular AAV evolution are discussed.

CRISPR-Cas systems for editing, regulating and targeting genomes

A modified version of the CRISPR-Cas9 system has been developed to recruit heterologous domains that can regulate endogenous gene expression or label specific genomic loci in living cells, which will undoubtedly transform biological research and spur the development of novel molecular therapeutics for human disease.

Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles.

A DNA shuffling-based approach for developing cell type-specific vectors through directed evolution and a unique immunological profile based on neutralizing antibody (NAb) titer and crossreactivity studies strongly supporting isolation of a synthetic laboratory-derived capsid variant are reported.

DNA shuffling of adeno-associated virus yields functionally diverse viral progeny.

Direct evolution can potentially yield unlimited numbers of new AAV variants with novel gene-delivery properties, and subsequent analysis of these variants can further extend basic knowledge of AAV biology.

Repurposing CRISPR/Cas9 for in situ functional assays.

The results establish Cas9 genome editing as a powerful and practical approach for positive in situ genetic screens for targeted gene disruption positive selection assays.

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

A single lentiviral system to express a Cas9 variant, a reporter gene and up to four sgRNAs from independent RNA polymerase III promoters that are incorporated into the vector by a convenient Golden Gate cloning method will be significant to enabling the potential of CRISPR/Cas9-based multiplex genome engineering in diverse cell types.

Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation

An online tool for the design of highly active sgRNAs for any gene of interest is provided, including a further optimization of the protospacer-adjacent motif (PAM) of Streptococcus pyogenes Cas9.